(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 45.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Intellia Therapeutics's revenue in 2024 is $36,275,000.On average, 13 Wall Street analysts forecast NTLA's revenue for 2024 to be $4,897,870,718, with the lowest NTLA revenue forecast at $1,175,381,333, and the highest NTLA revenue forecast at $9,850,906,513. On average, 11 Wall Street analysts forecast NTLA's revenue for 2025 to be $6,938,113,590, with the lowest NTLA revenue forecast at $864,957,645, and the highest NTLA revenue forecast at $20,182,345,050.
In 2026, NTLA is forecast to generate $11,426,955,448 in revenue, with the lowest revenue forecast at $5,784,644,517 and the highest revenue forecast at $16,904,155,575.